Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma

[1]  B. Zee,et al.  Effect of daily etidronate on the osteolysis of multiple myeloma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Kanis,et al.  The Use of Clodronate in Disorders of Calcium and Skeletal Metabolism1 , 1990 .

[3]  R. Bataille,et al.  Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Howell,et al.  Bisphosphonates and bone metastases. , 1988, British Journal of Cancer.

[5]  J. Koeller,et al.  Clodronate. A randomized study in the treatment of cancer-related hypercalcemia. , 1987, Archives of internal medicine.

[6]  J. Kanis,et al.  Treatment of malignant hypercalcaemia with clodronate. , 1985, British Journal of Cancer.

[7]  F. Preston,et al.  The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma , 1983, British journal of haematology.

[8]  C. Blomqvist,et al.  LONG-TERM CONTROLLED TRIAL WITH DIPHOSPHONATE IN PATIENTS WITH OSTEOLYTIC BONE METASTASES , 1983, The Lancet.

[9]  E. Siris,et al.  Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. , 1981, Annals of internal medicine.

[10]  J. Kanis,et al.  Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone. , 1980, Arthritis and rheumatism.

[11]  J. Coindre,et al.  Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue. , 1980, Arthritis and rheumatism.

[12]  F. Preston,et al.  EFFECT OF DICHLOROMETHYLENE DIPHOSPHONATE IN PAGET'S DISEASE OF BONE AND IN HYPERCALCÆMIA DUE TO PRIMARY HYPERPARATHYROIDISM OR MALIGNANT DISEASE , 1980, The Lancet.

[13]  E. Vignon,et al.  Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. , 1980, The Journal of clinical investigation.

[14]  E. Siris,et al.  Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. , 1980, The New England journal of medicine.

[15]  Elisa T. Lee,et al.  A computer program for comparing K samples with right-censored data. , 1972, Computer programs in biomedicine.

[16]  J. Kanis,et al.  Rationale for the use of bisphosphonates in bone metastases. , 1991, Bone.

[17]  J. Kanis,et al.  Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy. , 1991, Bone.

[18]  E. Ascari,et al.  LONG‐TERM EFFECTS OF PARENTERAL DICHLOROMETHYLENE BISPHOSPHONATE (CL2MBP) ON BONE DISEASE OF MYELOMA PATIENTS TREATED WITH CHEMOTHERAPY , 1990, Hematological oncology.

[19]  R. Rosso,et al.  Disodium clodronate in the treatment of pain due to bone metastases. , 1990, International journal of clinical pharmacology research.

[20]  G. Mundy,et al.  Bone resorption and turnover in health and disease. , 1987, Bone.

[21]  M. Chapuy,et al.  Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate. , 1983, Metabolic bone disease & related research.

[22]  E. Vignon,et al.  Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma. , 1982, Metabolic bone disease & related research.

[23]  J. Kanis,et al.  The pathophysiology of hypercaemia , 1980 .

[24]  R. Kyle.  Multiple myeloma: review of 869 cases. , 1975, Mayo Clinic proceedings.